Skip to main content

Table 1 Characteristics of adverse event reports

From: Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

  Saxagliptin (%) Sitagliptin (%) Linagliptin (%) Vildagliptin (%)
Number of events 680 7811 802 347
Gender
 Female 313 (46) 3703 (47) 379 (47) 159 (46)
 Male 340 (50) 3233 (41) 360 (45) 171 (49)
 Unknown 27 (4) 875 (11) 63 (8) 17 (5)
Age (year)
 <18 0 (0) 8 (0) 3 (0) 0 (0)
 18–44 35 (5) 39 (0) 31 (4) 18 (5)
 45–64 273 (40) 2286 (29) 169 (21) 91 (26)
 65–74 143 (21) 3386 (43) 166 (21) 70 (20)
 ≥ 75 98 (14) 1000 (13) 171 (21) 82 (24)
 Unknown 131 (19) 1092 (14) 262 (33) 86 (25)
Outcome of AEs
 Hospitalization (initial or prolonged) 188 (28) 2198 (28) 253 (32) 149 (43)
 Disability 18 (3) 373 (5) 30 (4) 11 (3)
 Life-threatening 23 (3) 473 (6) 36 (4) 21 (6)
 Death 25 (4) 483 (6) 37 (5) 50 (14)